NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 1 நாளுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Poly Medicure Q2 FY27 வருவாய் 31% உயர்ந்து ₹581 கோடி; FY30-க்குள் இரட்டிப்பு இலக்கு மீண்டும் உறுதி
Poly Medicure தனது Q2 FY27 வருவாய் அழைப்பின் (earnings call) டிரான்ஸ்கிரிப்டைச் சமர்ப்பித்துள்ளது. இதில் ஒருங்கிணைந்த காலாண்டு வருவாய் 31% உயர்ந்து ₹581 கோடியாகவும், PAT ₹95 கோடியாகவும் இருந்தது. ஒருங்கிணைந்த H1 FY27 வருவாய் 31% உயர்ந்து ₹1,106 கோடியாக இருந்தது (14% ஆர்கானிக் வளர்ச்சி), வெளிநாட்டு செயல்பாடுகள் மற்றும் சமீபத்திய கையகப்படுத்தல்கள் இதற்கு ஆதரவாக இருந்தன. நிறுவனத்திடம் ₹377 கோடி ஒருங்கிணைந்த கடனுக்கு எதிராக ₹839 கோடி பணப்புழக்க வசதி உள்ளது (நிகர பணம் ₹460 கோடி). ஆண்டு மூலதனச் செலவு வழிகாட்டுதல் ₹200-₹225 கோடியாக தொடர்கிறது; இது FY30-க்குள் வருவாயை இரட்டிப்பாக்கும் நிர்வாகத்தின் இலக்கை ஆதரிக்கிறது.
உச்சம் நம்பிக்கை
என்ன மாறியதுPoly Medicure, நவம்பர் 05, 2026 அன்று நடைபெற்ற தனது Q2 மற்றும் H1 FY27 வருவாய் அழைப்பின் முழு விவாதத்தையும் டிரான்ஸ்கிரிப்டையும் பகிர்ந்துள்ளது.
ஏன் இது முக்கியம்Citieffe மற்றும் PendraCare ஆகியவற்றின் கையகப்படுத்தல் ஒருங்கிணைப்பு மற்றும் ஏற்றுமதி லாப வரம்பு விரிவாக்கத்தால் 31% மேல்நிலை வருவாய் வளர்ச்சி இருப்பது, பல ஆண்டு வருவாய் இரட்டிப்பு இலக்கை நோக்கி நிறுவனம் பாதையில் இருப்பதைக் காட்டுகிறது.
Q2 FY27 ஒருங்கிணைந்த வருவாய்: ₹581 கோடிQ2 FY27 ஒருங்கிணைந்த PAT: ₹95 கோடிH1 FY27 ஒருங்கிணைந்த EBITDA: ₹266 கோடிஒருங்கிணைந்த நிகர பணம் நிலை: ₹460 கோடிFY27 மூலதனச் செலவு வழிகாட்டுதல்: ₹200 கோடி-₹225 கோடி
📅 குறுகிய காலம்Q2 FY27-ல் 31% வருவாய் வளர்ச்சி மற்றும் மூலப்பொருள் செலவு அழுத்தங்களுக்கு எதிராக மொத்த லாப வரம்பைத் திறம்படத் தக்கவைத்தது ஆகியவற்றின் பின்னணியில் நிலையான முதல் நேர்மறை உணர்வு.
📈 நீண்ட காலம்கார்டியாலஜி மற்றும் ஆர்த்தோபெடிக்ஸ் போன்ற அதிக லாப வரம்புள்ள பிரிவுகளில் விரிவாக்கம், UK மற்றும் பிரேசில் துணை நிறுவனங்களின் விரிவாக்கத்துடன் சேர்ந்து, FY30-க்குள் வருவாயை இரட்டிப்பாக்கும் திட்டத்திற்கு ஆதாரமாக உள்ளது.
⚠ அபாய எச்சரிக்கைகள்
உள்நாட்டு டயாலிசிஸ் பிரிவில் சீன டம்பிங் அழுத்தம்; ஒழுங்குமுறை நடவடிக்கை நிலுவையில் உள்ளது
சமீபத்தில் கையகப்படுத்தப்பட்ட வெளிநாட்டு நிறுவனங்களில் செயல்படுத்தல் மற்றும் ஒருங்கிணைப்பு அபாயங்கள்
👀 கவனிக்க வேண்டியவை
புதிய UK மற்றும் பிரேசில் துணை நிறுவனங்களின் செயல்பாட்டு முன்னேற்றம் மற்றும் லாப வரம்புப் பங்களிப்பையும், renal பிரிவில் தாக்கல் செய்யப்பட்ட ஆன்டி-டம்பிங் மனுவின் முடிவையும் கண்காணியுங்கள்.
Polymed H1 FY27 Revenue Up 30.6% to Rs 1,105.9 Cr; Non-Infusion Mix Expands to 51%
Poly Medicure released its Q2/H1 FY27 investor presentation, reporting consolidated operating revenue of Rs 1,105.9 Cr for H1 FY27, up 30.6% YoY (14.4% organic growth). Total operating revenue for Q2 FY27 stood at Rs 580.5 Cr compared to Rs 443.9 Cr in Q2 FY26. Segments beyond core infusion therapy expanded to drive 51% of total revenue in H1 FY27, led by strong growth in Cardiology (Rs 55.6 Cr) and Orthopaedics (Rs 91.9 Cr). The company maintains a strong liquidity position with cash and equivalents of Rs 839.1 Cr as of September 30, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுPoly Medicure shared its H1 FY27 investor presentation highlighting portfolio diversification away from core infusion therapy and steady progress in higher-margin cardiology and orthopaedics verticals.
ஏன் இது முக்கியம்Demonstrates structural revenue diversification (51% non-infusion) and confirms healthy organic expansion alongside acquisitions, backed by a strong cash pile of Rs 839.1 Cr.
📅 குறுகிய காலம்Presents a solid operational update showcasing strong top-line numbers for Q2 and H1 FY27, likely supporting investor sentiment.
📈 நீண்ட காலம்Successfully executing on the 'Polymed 3.0' vision to double revenue by 2030 through diversification into cardiology, renal care, and orthopaedics while expanding direct-sales footprint globally.
⚠ அபாய எச்சரிக்கைகள்
Working capital intensity with inventory stretching to 73 days and 136-day cash conversion cycle
Persistent dumping pressure from China in the renal care segment
👀 கவனிக்க வேண்டியவை
Track the integration and organic margin profile of acquired businesses (PendraCare and Citieffe) along with working capital cycle normalization (currently at 136 days).
POLYMED Q2 FY27 Consolidated Revenue Up 30.8% YoY to ₹580.5 Cr, PAT at ₹95.1 Cr
Poly Medicure reported Q2 FY27 consolidated revenue from operations of ₹580.53 Cr, up 30.8% YoY from ₹443.88 Cr in Q2 FY26. Consolidated profit after tax grew 3.6% YoY to ₹95.13 Cr compared to ₹91.80 Cr in Q2 FY26, with PAT margin contracting due to higher raw material and other operational expenses. Basic EPS for the quarter stood at ₹9.38 compared to ₹9.06 a year ago. Additionally, the board classified wholly owned subsidiary Poly Medicure B.V., Netherlands, as a material subsidiary as its net worth surpassed 10% of consolidated net worth.
உச்சம் நம்பிக்கை
என்ன மாறியதுReported Q2 FY27 earnings showing healthy top-line growth but subdued profit growth, alongside the classification of Dutch subsidiary Poly Medicure B.V. as a material subsidiary.
ஏன் இது முக்கியம்Top-line expanded over 30% YoY, but cost increases dampened operational leverage, keeping PAT growth modest at 3.6% YoY.
📅 குறுகிய காலம்Market may view top-line expansion positively, but margin contraction (subdued PAT growth relative to 31% sales growth) could limit near-term price momentum.
📈 நீண்ட காலம்Sustained revenue momentum supports management's growth guidance, though profitability depends on integrating overseas acquisitions and managing input costs.
⚠ அபாய எச்சரிக்கைகள்
Margin pressure from rising consumption of raw materials and operational expenses
Certain overseas step-down subsidiaries (Risor Holding B.V. and Medistream SA) operated at a combined net loss of ₹10.51 Cr in Q2
👀 கவனிக்க வேண்டியவை
Track margin recovery in upcoming quarters and monitor the performance and integration of overseas subsidiaries (such as Poly Medicure B.V. and its step-down units).
Poly Medicure reported its Q1 FY27 earnings call details, maintaining full-year consolidated revenue guidance of ₹2,300 to ₹2,400 Cr (vs ₹2,024 Cr TTM) and consolidated EBITDA margins of 23% to 25%. Q1 consolidated revenue grew 30.3% YoY to ₹525 Cr, bolstered by ₹72.3 Cr in revenue from newly acquired businesses (PendraCare and Citieffe). The company plans ₹200 to ₹225 Cr in FY27 capex (~10-11% of TTM revenue) for manufacturing facilities under construction in Faridabad and Noida, backed by ₹855 Cr in liquid reserves. Under its 'PolyMed 3.0' roadmap, management aims to double revenues by FY30 via organic and inorganic expansion in high-complexity devices.
உச்சம் நம்பிக்கை
என்ன மாறியதுManagement formalized its PolyMed 3.0 vision to double revenue by FY30 and reiterated full-year FY27 guidance of ₹2,300-2,400 Cr.
ஏன் இது முக்கியம்Demonstrates successful integration of recent acquisitions into higher-margin cardiology/orthopedic segments while keeping balance sheet liquidity robust at ₹855 Cr.
FY27 Cons. Revenue Guidance: ₹2,300 to ₹2,400 CrFY27 Capex Plan: ₹200 to ₹225 CrFY27 Capex vs TTM Revenue: ~10.5%Q1 Cons. Revenue: ₹525 கோடிCash & Liquid Reserves: ₹855 கோடிQ1 M&A Revenue Contribution: ₹72.3 கோடி
📅 குறுகிய காலம்Operating margins remain robust at 24.1% consolidated, though Middle East shipping bottlenecks and higher employee costs from Haryana wage revisions will be factors to track in Q2.
📈 நீண்ட காலம்Transition toward high-complexity medtech verticals (cardiology, oncology, orthopedics) reduces concentration risk in basic infusion disposables and supports long-term margin resilience.
⚠ அபாய எச்சரிக்கைகள்
Logistical disruptions causing a 32% decline in Middle East export sales.
Pricing competition from Chinese imports in the renal segment.
Employee cost inflation following a 35% hike in Haryana minimum wages.
👀 கவனிக்க வேண்டியவை
Monitor execution milestones on Faridabad and Noida plant additions, normalization of Middle East logistics, and the government's antidumping investigation on Chinese dialyzers.
Poly Medicure Fixes Aug 29, 2026 Record Date for ₹3.50/Share Final Dividend
Poly Medicure Limited has fixed Saturday, August 29, 2026, as the record date for determining shareholder eligibility for a final dividend of ₹3.50 per equity share (face value ₹5 each) for FY 2025-26. The Register of Members and Share Transfer Books will remain closed from August 30, 2026, to September 05, 2026. The dividend is subject to approval by shareholders at the upcoming Annual General Meeting scheduled for September 05, 2026. On an FY26 EPS of ₹31.79, this payout represents a dividend payout ratio of approximately 11.0%.
உச்சம் நம்பிக்கை
என்ன மாறியதுPoly Medicure established the record date and book closure timeline for its FY26 final dividend of ₹3.50 per share.
ஏன் இது முக்கியம்Determines shareholder entitlement to dividend distribution; represents a regular cash return with a dividend yield of ~0.20% at the current market price of ₹1,786.20.
Final Dividend per share: ₹3.50Face Value per share: ₹5.00ரெக்கார்ட் தேதி: 29-ஆக.-2026AGM Date: 05-செப்.-2026Dividend vs FY26 EPS: ~11.0%
📅 குறுகிய காலம்The stock will adjust for the ₹3.50 ex-dividend value around the August 29, 2026 record date.
📈 நீண்ட காலம்Limited; this is a routine corporate action reflecting standard capital return policy.
👀 கவனிக்க வேண்டியவை
Investors seeking dividend eligibility must hold shares before the ex-dividend date; track AGM voting outcomes on September 05, 2026, for final approval.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Poly Medicure reported a strong 30.3% YoY growth in consolidated revenue to ₹525.4 Cr for Q1 FY27, driven by the Cardiology segment and recent acquisitions. However, consolidated PAT declined by 8.4% to ₹85.3 Cr, impacted by a 55.1% increase in depreciation and a 120.4% rise in finance costs following expansion activities. EBITDA margins contracted by 257 bps to 24.1% due to pricing pressure in the Renal segment from Chinese competitors. The company maintains a robust liquidity position with approximately ₹850 Cr in cash to fund its 'Polymed 3.0' growth phase.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned into 'Polymed 3.0', shifting focus toward high-complexity verticals like Cardiology and Orthopaedics, which now contribute significantly to the revenue mix.
ஏன் இது முக்கியம்Diversification is reducing reliance on the core Infusion Therapy segment (now 50% of revenue vs 58% YoY), moving the company up the value chain into advanced medical technologies.
📅 குறுகிய காலம்The market may focus on the margin compression and PAT decline in the immediate term, despite the strong top-line performance.
📈 நீண்ட காலம்The structural shift toward specialized medical devices and inorganic expansion supports the company's long-term target of 18-20% CAGR.
⚠ அபாய எச்சரிக்கைகள்
Pricing pressure from Chinese players in the Renal segment
Geopolitical risks in the Middle East impacting export volumes
Increased interest and depreciation costs from recent capital expenditure
👀 கவனிக்க வேண்டியவை
Monitor the outcome of the anti-dumping investigation initiated by the Government on dialyzers from China and Malaysia, which could protect domestic margins. Watch for the stabilization of operating margins as the high-growth Cardiology and Orthopaedics segments scale up.
CRISIL Revises Poly Medicure's Outlook to 'Positive'; Reaffirms AA- Rating
CRISIL Ratings has revised the outlook on Poly Medicure Limited's long-term bank facilities to 'Positive' from 'Stable', while reaffirming the rating at 'CRISIL AA-'. The short-term rating has also been reaffirmed at 'CRISIL A1+', the highest possible for short-term instruments. Furthermore, the total rated bank loan facilities have been enhanced to Rs. 500 crore from the previous Rs. 400 crore. This outlook revision suggests a potential rating upgrade in the medium term, reflecting improved creditworthiness and financial stability.
முக்கிய அம்சங்கள்
Long-term rating outlook revised to 'Positive' from 'Stable' with 'CRISIL AA-' reaffirmed.Short-term rating reaffirmed at 'CRISIL A1+', indicating strong liquidity and low credit risk.Total bank loan facilities enhanced by 25% to Rs. 500 crore from Rs. 400 crore.Ratings cover facilities across major lenders including State Bank of India, HDFC Bank, and HSBC.
👀 கவனிக்க வேண்டியவை
The outlook revision to 'Positive' is a bullish signal indicating a potential credit rating upgrade, which could lead to lower borrowing costs. Investors should maintain a positive stance as this reflects the company's strengthening financial profile.
Poly Medicure Appoints Indranil Mukherjee as CEO for Asia Pacific and India Business
Poly Medicure Limited has appointed Mr. Indranil Mukherjee as the Chief Executive Officer for its Asia Pacific and India Business, effective June 1, 2026. Mr. Mukherjee is a seasoned medical technology executive with over 30 years of experience, including leadership roles at B. Braun and Translumina Therapeutics. He has a proven track record of managing large-scale operations, including three manufacturing plants and a workforce of over 2,000 employees. This strategic hire is expected to strengthen the company's market position and drive growth in its core geographic segments.
முக்கிய அம்சங்கள்
Mr. Indranil Mukherjee appointed as CEO - Asia Pacific and India Business effective June 1, 2026.Brings over 30 years of leadership experience in medical technology, covering critical care, infusion therapy, and renal care.Previously served as Managing Director at B. Braun Group in India, overseeing 3 manufacturing plants and 2,000+ colleagues.Extensive global experience including roles in Germany and Malaysia, with expertise in M&A and organizational restructuring.
👀 கவனிக்க வேண்டியவை
The appointment of a highly experienced industry veteran is a positive signal for the company's growth strategy in the Asia Pacific region. Investors should watch for potential improvements in operational efficiency and market expansion under his leadership.
Poly Medicure FY26 Consolidated Revenue Up 12.3% to ₹1,875 Cr; Guides ₹2,400 Cr for FY27
Poly Medicure reported a consolidated revenue growth of 12.3% for FY26, reaching ₹1,875 crores, with a strong 20% growth in the domestic business. The company is undergoing a strategic transition toward high-margin, high-technology segments like Cardiology and Renal, which now contribute 50% of total revenue. Management has provided robust guidance for FY27, targeting consolidated revenue of ₹2,300-₹2,400 crores, supported by the integration of acquisitions in Europe and Brazil. While raw material costs and logistics pose headwinds, the company maintains a strong cash reserve of ₹842 crores for future growth.
முக்கிய அம்சங்கள்
FY26 consolidated revenue grew 12.3% YoY to ₹1,875 crores, with Q4 revenue rising 21% to ₹534 crores.High-technology segments now account for 50% of revenue, up from 43% in the previous year.Management guided for FY27 consolidated revenue of ₹2,300-₹2,400 crores, implying ~25% growth.Standalone EBITDA margin for FY26 stood at 26.8%, hitting the upper end of the 25-27% guidance range.Company completed acquisitions of PendraCare, Citieffe, and Medyneo (Brazil) to expand global footprint.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's successful shift into high-margin medical devices and the integration of its recent international acquisitions. Monitor the impact of crude-linked raw material costs on gross margins in the upcoming quarters.
Poly Medicure Recommends Rs 3.50 Dividend; FY26 Consolidated Revenue Up 12% to Rs 1,534 Cr
Poly Medicure's Board has recommended a final dividend of Rs 3.50 per share (70% of face value) for FY 2025-26, subject to shareholder approval. The company reported a 12% year-on-year growth in consolidated revenue from operations, reaching Rs 1,534.28 crore for the full year. However, consolidated net profit for FY26 saw a marginal decline to Rs 322.14 crore compared to Rs 338.56 crore in FY25. The board also approved the re-appointment of PwC as internal auditors for the next fiscal year.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs 3.50 per equity share of face value Rs 5 for FY 2025-26Consolidated annual revenue from operations grew 12% YoY to Rs 1,534.28 croreConsolidated Net Profit for FY26 stood at Rs 322.14 crore versus Rs 338.56 crore in FY25Q4 FY26 consolidated revenue rose to Rs 420.97 crore from Rs 365.56 crore in the previous year's quarterRe-appointed PricewaterhouseCoopers Services LLP and Oswal Sunil & Co. as internal auditors for FY 2026-27
👀 கவனிக்க வேண்டியவை
Investors should maintain a hold position for steady dividend yields while monitoring the slight contraction in annual net profit despite healthy revenue growth. The margin pressure observed in the full-year results should be evaluated against the company's expansion and operational costs.
Poly Medicure reported a robust 20% year-on-year growth in consolidated revenue for FY26, reaching ₹1,715.13 crore. However, consolidated net profit for the full year saw a decline of 5.3%, falling to ₹320.73 crore from ₹338.56 crore in the previous fiscal. The company maintained its dividend payout, recommending ₹3.5 per equity share for FY26. While top-line growth remains strong, the bottom-line was impacted by higher total expenses, which rose to ₹1,24,868.12 lacs on a standalone basis for the year.
முக்கிய அம்சங்கள்
Consolidated Revenue from Operations for FY26 increased 20% YoY to ₹1,715.13 crore.Consolidated Net Profit for FY26 declined by 5.3% to ₹320.73 crore compared to FY25.Board recommended a final dividend of ₹3.5 per equity share (70% of face value of ₹5).Standalone Q4 FY26 Net Profit stood at ₹81.25 crore, a decrease from ₹86.66 crore in Q4 FY25.Total Consolidated Assets grew significantly to ₹3,918.57 crore as of March 31, 2026, from ₹3,192.45 crore YoY.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to manage rising operational costs as profit margins have contracted despite strong revenue growth. The steady dividend and significant asset expansion suggest long-term capacity building, but short-term bottom-line pressure warrants a cautious watch.
Poly Medicure Acquires 100% Stake in Brazil's MEDYNEO for R$ 180,000
Poly Medicure's Brazilian subsidiary has acquired 100% equity in MEDYNEO COMERCIO DE PRODUTOS PARA SAUDE LTDA for a cash consideration of R$ 180,000. While MEDYNEO is a newly registered entity with no prior operations or turnover, it holds essential licenses and permits for the importation and commercialization of medical devices in Brazil. This acquisition serves as a strategic entry point, allowing Poly Medicure to bypass regulatory delays and immediately begin distribution activities in the Brazilian market. The transaction was completed on April 29, 2026, making MEDYNEO a step-down subsidiary of the company.
முக்கிய அம்சங்கள்
Acquisition of 100% equity stake in MEDYNEO by Polymed Brazil LTDA for R$ 180,000 (approx. ₹30 Lakhs).Target entity provides immediate access to necessary operating licenses for medical device distribution in Brazil.MEDYNEO is a clean entity with no past activities, operations, employees, or liabilities.The acquisition was completed and operational control taken over effective April 29, 2026.Strategic move to expand the company's international footprint in the Latin American medical device market.
👀 கவனிக்க வேண்டியவை
Investors should view this as a low-cost, high-utility strategic move to accelerate growth in the Brazilian market. Monitor the company's upcoming quarterly reports for updates on revenue contributions from the Brazilian geography.
Poly Medicure 9M FY26 Revenue Up 9.1% to ₹1,341 Cr; Domestic Sales Grow 17.6%
Poly Medicure reported a 9.1% YoY increase in consolidated revenue to ₹1,340.7 crore for 9M FY26, driven by strong domestic growth of 17.6%. While Gross Profit margins improved to 68.8%, Operating EBITDA margins contracted slightly to 25.8% due to higher employee and acquisition-related expenses. The company is aggressively expanding into high-growth areas like Cardiology and Orthopaedics through recent acquisitions of Pendracare and Citieffe. With 15 manufacturing plants and a pipeline of 100+ products, the company aims to maintain its leadership as India's largest medical device exporter.
முக்கிய அம்சங்கள்
Consolidated 9M FY26 revenue reached ₹1,340.7 crore, a 9.1% increase over the previous year.Domestic revenue showed robust growth of 17.6%, while international revenue grew by 5.8%.Gross Profit margin improved by 192 bps to 68.8%, though EBITDA margin dipped to 25.8%.Strategic expansion into Cardiology and Orthopaedics via acquisitions of Pendracare (Netherlands) and Citieffe (Italy).Manufacturing capacity stands at 1.8 billion+ devices per year across 15 global plants.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of recent European acquisitions and the ramp-up of the new Haridwar and upcoming Palwal plants. The shift towards high-complexity segments like Cardiology and Orthopaedics suggests potential for long-term margin expansion.
Poly Medicure Reports Zero Deviation in Utilization of Rs 1,000 Crore QIP Proceeds
Poly Medicure Limited has confirmed that there are no deviations in the utilization of the Rs 99,999.98 lakh raised through its August 2024 QIP. As of December 31, 2025, the company has utilized Rs 47,431.17 lakh of the total net proceeds. Notably, the company has fully utilized the Rs 25,026.84 lakh allocated for inorganic initiatives, while the majority of the capital expenditure for manufacturing facilities (Rs 46,446.30 lakh) remains unspent.
முக்கிய அம்சங்கள்
Total funds raised via QIP in August 2024 amounted to Rs 99,999.98 lakh at an issue price of Rs 1,880 per share.Inorganic growth initiatives allocation of Rs 25,026.84 lakh has been 100% utilized as of December 31, 2025.Capital expenditure for manufacturing facilities shows slow deployment with only Rs 3,526.86 lakh spent out of Rs 49,973.16 lakh allocated.Actual issue expenses were Rs 1,465.61 lakh, which was lower than the estimated Rs 1,500 lakh, with the surplus moved to General Corporate Purposes.Total unutilized funds remaining in the monitoring account stand at approximately Rs 51,103 lakh.
👀 கவனிக்க வேண்டியவை
Investors should track the timeline for the remaining Rs 464 crore capex deployment, as this will drive future capacity and revenue growth. The full utilization of inorganic funds indicates that the company has already committed capital toward strategic acquisitions or partnerships.
Poly Medicure Q3 FY26: Revenue Up 16.4% to ₹494 Cr; Strategic Shift to High-Tech MedTech
Poly Medicure reported a 16.4% YoY revenue growth in Q3 FY26, reaching ₹494 crores, with gross margins expanding by 300 bps to 68.4%. The company is successfully transitioning from low-tech products to high-complexity segments like cardiology and orthopedics, bolstered by the acquisitions of PendraCare and Citieffe. Domestic private market growth remains strong at 22.5%, while the company is deliberately reducing lower-margin government business. With ₹840 crores in liquidity, management expects H2 FY26 revenue to be 20% higher than H1.
முக்கிய அம்சங்கள்
Consolidated Q3 revenue grew 16.4% YoY to ₹494 crores with a strong gross margin of 68.4%.Received DCGI approvals for high-end IVL and DEB products with ASPs exceeding ₹1,15,000.Completed acquisitions of PendraCare and Citieffe, expanding footprint in European and US markets.Domestic private business grew 22.5% YoY, while government business was reduced by 18% to improve margins.Maintains strong liquidity of ₹840 crores to fund future organic and inorganic growth strategies.
👀 கவனிக்க வேண்டியவை
Investors should favor the company's strategic pivot toward high-margin, high-complexity medical devices which creates higher entry barriers. Monitor the integration of European acquisitions and the scaling of the US business as key catalysts for future growth.
Poly Medicure Q3 FY26 Revenue Up 16.4% to ₹493.7 Cr; PAT Dips 16.9% on One-time Costs
Poly Medicure reported a 16.4% YoY growth in consolidated revenue to ₹493.7 Cr for Q3 FY26, driven by strong performance in European markets and the 'Others' segment. However, PAT declined by 16.9% YoY to ₹70.8 Cr, primarily due to ₹6.5 Cr in acquisition-related expenses and a ₹6.8 Cr one-time provision for the Revised Labour Code. The quarter saw the consolidation of PendraCare and Citieffe groups, which contributed to a 25.7% surge in European revenue. While operating EBITDA margins contracted to 24.2%, the 9M FY26 margin of 25.8% remains within the management's guidance range.
முக்கிய அம்சங்கள்
Consolidated Revenue grew 16.4% YoY to ₹493.7 Cr, with Domestic revenue increasing 16.2%.PAT fell 16.9% YoY to ₹70.8 Cr, impacted by ₹13.3 Cr in combined one-time acquisition and labor code expenses.European revenue surged 25.7% YoY to ₹162.2 Cr following the integration of PendraCare and Citieffe.Received DCGI regulatory approvals for Intravenous Lithotripsy System (IVL) and Drug Eluting Balloon (DEB).Maintained a strong balance sheet with cash and equivalents of ₹839.8 Cr and 9M FY26 capex of ₹234 Cr.
👀 கவனிக்க வேண்டியவை
Investors should look past the one-time acquisition costs and focus on the successful integration of European subsidiaries and the rollout of high-value products like IVL. Monitor if EBITDA margins return to the 26-27% range in the coming quarters as synergies materialize.
Poly Medicure Q3 Consolidated PAT at ₹91.55 Cr; Grants 2,000 ESOPs
Poly Medicure reported a consolidated total income of ₹452.51 crore for Q3 FY26, showing steady performance. The company's Net Profit for the quarter stood at ₹91.55 crore, despite a one-time exceptional provision of ₹6.80 crore related to new Labour Code requirements. The company is actively integrating its recent acquisitions of Pendracare and Citieffe Group, which are now reflected in the consolidated financials. Additionally, the board approved 2,000 new stock options and provided an update on the utilization of the ₹1,000 crore QIP proceeds.
முக்கிய அம்சங்கள்
Consolidated Total Income for Q3 FY26 reached ₹452.51 crore, up from ₹442.89 crore in the preceding quarter.Consolidated Net Profit for the quarter was ₹91.55 crore with a Diluted EPS of ₹9.06.Recognized an exceptional item of ₹680.40 lacs (₹6.80 crore) as provision for past service costs under new Labour Codes.Utilized ₹250.26 crore of QIP proceeds for inorganic initiatives and ₹35.26 crore for capital expenditure.Maintains a strong liquidity position with ₹510.99 crore of QIP funds still invested in liquid mutual funds and FDs.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful integration of the European acquisitions which are expected to drive future growth. The significant unutilized QIP capital suggests further expansion or inorganic opportunities are likely in the near term.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
